VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
APYXApyx Medical Corporation
$4.50$188M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAPYXBalance Sheet

Apyx Medical Corporation (APYX) Balance Sheet

30Y historyFree accessUpdated daily

The company's financial leverage has intensified, with the debt-to-equity ratio rising to 3.02 in 2026Q1 from 1.43 in 2023Q4, reflecting a concerning trend of capital structure erosion.

APYX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets54.8M58.47M56.44M70.36M42.97M60.74M66.09M76.66M89.52M22.55M26.54M22.04M15.37M19.82M15.97M16.48M14.91M13.21M12.11M11.46M10.17M7.33M6.97M5.24M4.68M4.71M3.93M3.7M3.03M2.09M2.06M
Cash & Short-Term Investments31.14M31.74M31.74M43.65M10.19M30.87M41.91M58.81M78.14M9.95M14.46M11.8M5.73M7.92M4.16M4.88M3.83M2.15M2.56M3.53M2.95M1.3M2.29M306.14K379.21K578.35K278.66K415.07K278.67K48.25K120.9K
Cash Only31.14M31.74M31.74M43.65M10.19M30.87M41.91M58.81M16.47M9.95M14.46M11.8M5.73M7.92M4.16M4.88M3.83M2.15M2.56M3.53M2.95M1.3M2.29M306.14K379.21K578.35K278.66K415.07K278.67K48.25K120.9K
Short-Term Investments0000000061.68M0000000000000000000000
Accounts Receivable12.76M16.78M15.48M14.02M18.25M21.16M17.33M9.22M5.08M4.86M4.73M2.92M1.99M1.99M2.87M2.22M2.11M2.57M2.99M2.53M2.82M2.32M1.95M1.71M1.35M1.2M1.26M1.21M1M791.83K856.4K
Days Sales Outstanding87.77115.87117.4697.77149.62159.21228.24119.19111.1245.5947.1736.1726.2730.737.9131.8331.8534.7438.8732.0338.5541.8434.837.6739.638.1746.1446.0243.3639.2141.76
Inventory9.54M8.6M7.56M9.92M11.8M6.78M4.05M5.05M5.21M6.53M6.16M5.96M5.73M8.41M7.98M8.18M7.61M6.77M5.84M4.52M3.61M3M2M2.45M2.36M2.42M1.99M1.68M1.48M953.13K854K
Days Inventory Outstanding85.4992.86147.31194.83279.99165.86144.86201.65322.82124.57120.12128.18111.85212.38178.37203.34194.9163.76131.1694.5181.9586.4858.3894.83119.67154.29158.4133.46102.1984.0675.39
Other Current Assets1.37M1.35M1.66M2.76M2.74M00375K130K3.03M779K0804K545K951K500K400K800K216.88K603.22K386.2K386.2K386.2K386.2K431.24K386.98K397.53K392.6K198.06K232.27K175K
Total Non-Current Assets8.23M8.37M8.4M8.88M8.8M7.98M8.02M8.01M6.09M8.44M8.57M9.41M9.47M13.35M12.21M11.76M12.87M14.37M13.67M7.36M6.52M4.44M4.05M3.99M3.82M3.86M3.99M3.65M7.63M1.74M1.84M
Property, Plant & Equipment6.33M6.62M6.74M7.15M7.59M6.87M7.21M7.62M5.79M6.41M6.45M6.81M6.95M7.06M7.23M7.18M7.43M8.81M7.13M3.42M3.22M2.6M2.12M1.9M1.56M1.53M1.55M1.43M2.16M1.44M1.42M
Fixed Asset Turnover8.52x7.99x7.14x7.33x5.87x7.06x3.84x3.70x2.88x6.07x5.68x4.33x3.98x3.35x3.83x3.54x3.26x3.06x3.94x8.41x8.29x7.79x9.68x8.71x7.98x7.50x6.40x6.69x3.90x5.12x5.28x
Goodwill00000000185K185K185K185K00000000000000004.12K40K62.7K
Intangible Assets000000006K1.69M1.73M1.83M1.94M2.08M2.17M2.29M3.2M4.93M5.21M3.89M3.28M1.82M1.6M1.65M1.77M1.82M1.88M1.89M4.97M257.55K348.3K
Long-Term Investments00000000-150K-187K0123K-3.81M120K0000-530.86M-8.19M00000000129.76K7.15K7.1K
Other Non-Current Assets1.9M1.75M1.66M1.73M1.22M1.11M807K391K114K159K212K430K415K674K1.01M783K711K465.71K1.34M44.44K21.21K21.21K338.81K437.7K491.22K508.4K553.42K327.08K355.76K7.15K7.1K
Total Assets63.02M66.84M64.84M79.24M51.77M68.72M74.11M84.68M95.61M30.99M35.11M31.45M24.83M33.18M28.18M28.24M27.79M27.58M25.78M18.82M16.69M11.77M11.02M9.23M8.5M8.58M7.91M7.34M10.66M3.84M3.9M
Asset Turnover0.91x0.79x0.74x0.66x0.86x0.71x0.37x0.33x0.17x1.25x1.04x0.94x1.11x0.71x0.98x0.90x0.87x0.98x1.09x1.53x1.60x1.72x1.86x1.79x1.46x1.34x1.26x1.31x0.79x1.92x1.92x
Asset Growth %-8.7%3.08%-18.17%53.05%-24.66%-7.27%-12.48%-11.44%208.54%-11.74%11.64%26.64%-25.15%17.72%-0.2%1.63%0.73%7%36.97%12.8%41.75%6.82%19.33%8.62%-0.91%8.4%7.76%-31.11%177.77%-1.57%8.28%
Total Current Liabilities9.45M11.7M10.72M12.74M11.85M13.21M9.15M12.24M7.7M5.97M5.27M4.12M3.77M2.91M1.92M2.39M2.14M2.47M2.32M1.7M2.09M1.83M1.41M1.4M1.6M1.58M1.52M1.33M1.36M1.54M1.4M
Accounts Payable2.63M3.06M2.62M2.71M2.67M2.63M1.51M2.44M1.42M1.58M1.61M1.21M1.55M1.06M803K1.08M951K589K1.32M807.44K916.25K868.21K620.15K679.79K478.67K373.38K439.14K402.25K385.56K399.09K787.5K
Days Payables Outstanding28.4433.0150.9353.2563.3564.3854.0397.3588.1430.2231.3326.1230.3326.7517.9426.9824.3714.2429.5916.8820.825.0518.0926.324.323.8134.883226.6835.269.52
Short-Term Debt441K428K00000140K0239K239K239K239K72K138K130K140K1.14M125K0161.95K348.33K31.67K35.34K557.13K672.31K572.93K663.57K569.19K804.76K198K
Deferred Revenue (Current)3.37M0693K488K853K533K07.91M000001.24M749K0714K3.99K24.54K56.39K173.99K141.59K36M112M396.95K499.85K0000-4.6K
Other Current Liabilities3.84M8.21M01.54M02.12M811K-2.5M3.8M2.38M2.6M2.12M1.78M1.61M677K937K776K621.22K50.17K86.08K91.2K036K112K165.21K32.7K507.85K264.15K000
Current Ratio5.80x5.00x5.26x5.52x3.63x4.60x7.22x6.26x11.62x3.77x5.03x5.35x4.08x6.81x8.31x6.90x6.98x5.34x5.23x6.73x4.87x4.01x4.93x3.73x2.93x2.99x2.58x2.78x2.23x1.36x1.48x
Quick Ratio4.79x4.26x4.56x4.74x2.63x4.09x6.78x5.85x10.95x2.68x3.87x3.90x2.56x3.92x4.16x3.48x3.42x2.60x2.71x4.08x3.14x2.37x3.51x1.99x1.46x1.45x1.27x1.52x1.15x0.74x0.87x
Cash Conversion Cycle144.83175.72213.84239.36366.27260.69319.07223.49345.81139.95135.96138.22107.79216.33198.34208.19202.38184.27140.43109.6799.7103.2675.1106.2134.98168.65169.67147.49118.8688.0747.63
Total Non-Current Liabilities40.49M40.31M39.79M39.58M2.13M1.51M1.1M1.18M140K2.98M3.62M3.92M16.37M8.93M3.37M3.73M3.88M3.96M4.67M326.34K418.15K140M348.32K380K411.66K00011.23K74.11K482.7K
Long-Term Debt35.09M34.85M33.89M33.19M0000140K2.6M2.83M3.07M3.17M3.19M3.28M3.63M3.88M3.96M4.14M000348.32K380K411.66K00011.23K74.11K482.7K
Capital Lease Obligations16.5M4.06M4.52M4.95M543K18K312K656K00000000000000000000000
Deferred Tax Liabilities00000000150K368K564K564K564K0000-531K530.86K8.19K00000000000
Other Non-Current Liabilities339K347K259K198K181K166K166K519K020K217K285K3.19M5.75M85K105K00-530.86K-81.85K418.15K0000000000
Total Liabilities49.94M52.01M50.51M52.32M13.98M14.71M10.25M13.42M7.84M8.96M8.89M8.04M20.14M11.85M5.29M6.12M6.02M6.43M6.99M2.03M2.51M1.83M1.76M1.78M2.01M1.58M1.52M1.33M1.37M1.61M1.88M
Total Debt39.46M39.34M38.76M38.5M796K305K676K1.13M140K2.83M3.07M3.31M3.41M3.26M3.42M4.22M4.02M5.09M4M0161.95K348.33K379.99K415.34K968.8K672.31K572.93K663.57K580.41K878.87K685.3K
Net Debt8.32M7.6M7.02M-5.15M-9.4M-30.57M-41.24M-57.68M-16.33M-7.12M-11.38M-8.49M-2.32M-4.67M-743K-664K197K2.94M1.44M-3.53M-2.79M-946.94K-1.91M109.2K589.59K93.95K294.27K248.5K301.74K830.62K564.4K
Debt / Equity3.02x2.65x2.70x1.43x0.02x0.01x0.01x0.02x0.00x0.13x0.12x0.14x0.73x0.15x0.15x0.19x0.18x0.24x0.21x-0.01x0.04x0.04x0.06x0.15x0.10x0.09x0.11x0.06x0.40x0.34x
Debt / EBITDA-10.90x-------------1.80x4.65x-2.89x1.77x-0.05x0.37x0.23x0.40x-0.61x0.62x--1.35x0.92x
Net Debt / EBITDA-2.30x--------------0.39x-0.73x-1.67x0.63x-1.23x-0.89x-1.00x-1.14x0.11x-0.08x0.32x--1.28x0.76x
Interest Coverage-0.66x-1.15x-2.95x-7.59x-1526.40x-1481.00x-420.93x-2478.50x-140.26x-100.75x-23.59x-32.83x-86.98x-24.11x4.59x1.08x-10.04x9.68x48.50x852.49x162.40x17.79x84.07x19.48x-9.78x8.94x7.93x--8.86x-6.34x
Total Equity13.09M14.83M14.34M26.92M37.79M54.01M63.86M71.26M87.77M22.03M26.22M23.4M4.69M21.33M22.89M22.12M21.77M21.15M18.79M16.79M14.18M9.94M9.26M7.45M6.49M7M6.39M6.01M9.29M2.22M2.02M
Equity Growth %-69.32%3.46%-46.75%-28.76%-30.02%-15.42%-10.38%-18.81%298.37%-15.98%12.04%398.59%-77.99%-6.84%3.52%1.62%2.89%12.59%11.89%18.42%42.64%7.4%24.25%14.77%-7.27%9.49%6.32%-35.25%317.51%10.12%389.98%
Book Value per Share0.310.350.400.781.091.571.872.092.550.700.960.840.261.211.291.251.251.191.100.950.840.630.550.550.450.470.400.430.670.260.26
Total Shareholders' Equity12.83M14.54M14.21M26.7M37.58M53.7M63.72M71.26M87.77M22.03M26.22M23.4M4.69M21.33M22.89M22.12M21.77M21.15M18.79M16.79M14.06M9.8M9.26M7.45M6.49M7M6.39M6.01M9.29M2.22M2.02M
Common Stock42K42K38K35K35K34K34K34K34K33K31K27K18K18K18K18K18K16.95K16.8K15.46K15.24K14.06K13.88K16.64K13.27K13.27K13.76K14.12K14.78K124.07K121.7K
Retained Earnings-91.23M-89.12M-77.91M-54.45M-35.73M-12.55M2.62M14.52M35.51M-28.5M-23.43M-19.48M-27.85M-9.63M-2.64M-3.26M-3.37M-1.83M-3.98M-5.66M-8.06M-10.74M-11.15M-12.66M-13.34M-12.83M-13.61M-14.11M-11.93M-10.86M-10.96M
Treasury Stock0000000000000000000000000000000
Accumulated OCI00000000-6.36M-6.71M-7.27M-6.87M-6.35M-5.67M-5.45M-5M0-88.97K-88.46K-3.02M-2.41M-1.93M-1.56M-1.29M-1.06M-867.46K-674K-535.53K-2K00
Minority Interest256K291K125K221K211K305K138K0000000000000120K140K000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent capital structure erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Eroding Equity Base Signals Weakness

As reported in recent financial statements, Apyx Medical's equity has contracted significantly from $26.7 million in 2023Q4 to $12.8 million in 2026Q1, reflecting a persistent trend of value destruction driven by ongoing operational losses that continue to weigh heavily on the company's overall balance sheet trajectory.

The consistent decline in shareholders' equity suggests that the company is failing to retain earnings, which is a concerning indicator for long-term solvency. Investors should monitor whether this downward trend in equity will necessitate further dilutive financing to maintain operations.

Leverage Ratios Reflect Financial Strain

Based on reported figures, the company's debt-to-equity ratio has surged from 1.43 in 2023Q4 to 3.02 in 2026Q1, indicating that the firm is increasingly reliant on debt financing to sustain its operations while its underlying equity base continues to shrink under the pressure of recurring losses.

This elevated leverage ratio suggests that the company's capital structure is becoming increasingly precarious. The reliance on debt in the absence of consistent profitability may limit future financial flexibility and increase the risk profile for equity holders.

Cash Runway Remains A Critical Concern

According to quarterly filings, cash reserves have declined from $43.7 million in 2023Q4 to $31.1 million in 2026Q1, highlighting a persistent cash burn that warrants close scrutiny as the company attempts to fund its commercial expansion without a clear path to self-sustaining operational cash flow.

While the current ratio remains relatively high, the absolute decline in cash balances suggests that the company is consuming its liquidity buffer to cover operating deficits. This trend implies that the company may face liquidity constraints if revenue growth does not accelerate to offset the current burn rate.

Accumulated Deficit Masks Operational Reality

As disclosed in the balance sheet, the accumulated deficit has ballooned to $91.2 million as of 2026Q1, which serves as a stark reminder that historical investments have yet to translate into a profitable business model, potentially misleading investors who focus solely on short-term revenue growth metrics.

The magnitude of the accumulated deficit suggests that the company has historically struggled to convert its R&D and marketing spend into sustainable returns. This persistent deficit may continue to act as a drag on the company's valuation until a fundamental shift in profitability is achieved.

APYX — Frequently Asked Questions

Quick answers to the most common questions about buying APYX stock.

What are the total assets of Apyx Medical Corporation (APYX)?

As of 2025, Apyx Medical Corporation (APYX) had total assets of $66.8M including $58.5M in current assets.

How much debt does Apyx Medical Corporation (APYX) have?

Apyx Medical Corporation (APYX) carries total debt of $39.3M, offset by $31.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Apyx Medical Corporation?

Apyx Medical Corporation (APYX) has total shareholders' equity (book value) of $14.5M ($0.35 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Apyx Medical Corporation's current ratio and liquidity?

Apyx Medical Corporation (APYX) reported a current ratio of 5.00x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.